Kornimate/medical-research-clean huggingface dataset:
evaluation of the effectiveness of the local application of lemon in the prevention of blisters in ultra-trail runners

Conditions: Blister of Foot; Sport Injury

Summary: for more than a decade, worldwide participation in ultra-marathons and ultra-trails (running races longer than the 42.195 km marathon) has been increasing. although considered benign, blisters are a common problem, with serious consequences and limiting performance. although blisters are a major factor limiting endurance performance, they are a reason for only 5.8% of ultra-trail runners to quit. while equipment is improving and participants are increasing and intensifying their training, there is no consensus on the prevention of blisters in ultra-trail running, even though it is the number one factor limiting sports performance. there are few prospective interventional studies on the prevention of blisters during outdoor activities. on many running forums, there is the hypothesis that lemon applied to the feet prevents the appearance of blisters. this hypothesis has never been scientifically studied. the investigators hypothesize that the local application of lemon allows a reduction in the number of blisters on ultra-trail. the objective of this blisters-stop 2 study is to evaluate the efficacy of local application of lemon in preventing the appearance of blisters.

the patients included will be runners registered in a trail of a distance greater than 40km for whom lemon will be applied on the friction zones of one foot as a preventive measure (28 days). the study is coordinated by ifremmont and the pays du mont blanc hospitals and 82 patients must be included in order to obtain statistical significance.

Eligibility criteria:
inclusion criteria: * ultra-trail participants with validated registration * major (≥ 18 years old) exclusion criteria: * presence of blisters or other skin lesions on the feet 28 days before the race * amputation of one or two feet * allergy to lemon * psychiatric disorders making comprehension impossible * lack of social security coverage
transcutaneous measurement of jaundice in the newborn

Conditions: Hyperbilirubinemia, Neonatal; Jaundice, Neonatal

Summary: prospective comparison of measurement of bilirubin in jaundiced newborns by a transcutaneous device (bilirubinometer) and laboratory analysis of blood samples. we hypothesise that correlation of the two measurements depend on bilirubin level, gestational age as well as postnatal age.

whenever a blood sample is drawn for measurement of bilirubin in a newborn, a transcutaneous measurement of skin yellow color will be made. such measurements will also be included in all infants when a crp-test (blood sample for c-reactive protein) has been ordered, as well as in connection with the routine blood sampling for metabolic screening. only infants where parents have given written consent for their infant will be included in the study.

Eligibility criteria:
inclusion criteria: * newborn infant admitted to normal newborn nursery exclusion criteria: * informed consent not obtained

Keywords: hyperbilirubinemia neonatal serum bilirubin transcutaneous bilirubin skin color
efficacy of cyclosporine for the prevention and treatment of dry eye symptoms following lasik or photorefractive keratectomy

Conditions: Dry Eye Syndromes

Summary: the purpose of this study is to evaluate the effect of topical cyclosporine ophthalmic solution 0.05% (restasis, allergan) on the signs and symptoms of dry eye in patients undergoing lasik or photorefractive keratectomy (prk).


Eligibility criteria:
inclusion criteria: * males or females \> 18 years old * mild-moderate symptoms of dry eye prior to surgery * scheduled to undergo bilateral lasik or prk * likely to complete all study visits and able to provide informed consent exclusion criteria: * prior use of topical cyclosporine within the last 1 year * known contraindications to any study medication or ingredients * female of child bearing potential not using reliable methods of birth control, or pregnant or lactating females. * ocular disorders * active ocular diseases or uncontrolled systemic disease * active ocular allergies

Keywords: dry eye
a clinical trial testing the efficacy of crizotinib versus standard chemotherapy pemetrexed plus cisplatin or carboplatin in patients with alk positive non squamous cancer of the lung

Conditions: Non Squamous Lung Cancer

Summary: this study will evaluate the anti-cancer effects of crizotinib when compared with standard chemotherapy in patients with alk positive lung cancer.


Eligibility criteria:
inclusion criteria: * proven diagnosis of locally advanced not suitable for local treatment, recurrent and metastatic non-squamous cell carcinoma of the lung * positive for translocation or inversion events involving the alk gene locus * no prior systemic treatment for locally advanced or metastatic disease; patients with brain metastases only if treated and neurologically stable with no ongoing requirement for corticosteroids * evidence of a personally signed and dated informed consent document and willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures including completion of patient reported outcome \[pro\] measures. * 18 years of age or older with the exception of india which has an upper age limit of 65 years old exclusion criteria: * current treatment on another therapeutic clinical trial. * prior therapy directly targeting alk. * any of the following within the 3 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack. - - appropriate treatment with anticoagulants is permitted. * ongoing cardiac dysrhythmias of nci ctcae grade \>=2, uncontrolled atrial fibrillation of any grade, or qtc interval \>470 msec. * pregnancy or breastfeeding. * use of drugs or foods that are known potent cyp3a4 inducers/inhibitors concurrent use of drugs that are cyp3a4 substrates with narrow therapeutic indices. * known hiv infection * known interstitial lung disease or interstitial fibrosis * other severe acute or chronic medical conditions (including severe gastrointestinal conditions such as diarrhea or ulcer) or psychiatric conditions, or laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration, and which would, therefore, make the patient inappropriate for entry into this study

Keywords: open label randomized phase 3 first line treatment non squamous lung cancer alk translocation event positive
study of nitazoxanide suspension in the treatment of diarrhea caused by enteric viruses in children

Conditions: Rotavirus Infection; Adenoviridae Infection; Norovirus Infection

Summary: the purpose of this study is to determine the effect of nitazoxanide suspension in treating diarrhea caused by enteric viruses in children less than 12 years of age.


Eligibility criteria:
inclusion criteria: * age \<12 years. * patients with diarrhea (defined as 3 or more stools per day with liquid or semi-solid consistency, the number and consistency of stools being unusual for that person). * stool positive for adenovirus, norovirus or rotavirus by elisa. exclusion criteria: * females who are pregnant, suspected of being pregnant or breastfeeding. * other identified causes of diarrhea at screening. * serious systemic disorders incompatible with the study.
intra-articular autologous bone marrow mesenchymal stem cells transplantation to treat mild to moderate osteoarthritis

Conditions: Osteoarthritis

Summary: osteoarthritis is a progressively degenerative disease resulting in increasing pain, impairment and ultimately disability. while the available treatments seek to ameliorate pain or improve mobility, these treatments rarely modify the course of the disease, but rather attend to its consequences. for early stage osteoarthritis, treatment is largely limited to addressing the symptoms of inflammation with non-steroidal anti-inflammatory drugs (nsaids). these drugs do not stop the progression of the condition or regenerates damaged cartilage. this is a randomized and open labelled study aimed to determine the efficacy of intra-articular implantation of autologous bone marrow-derived mesenchymal stem cells in patients with mild to moderate osteoarthritis.


Eligibility criteria:
inclusion criteria: * diagnosed with mild to moderate osteoarthritis based on kellgren-lawrence radiographic classification * has a history of joint swelling, pain, stiffness, altered gait and loss of motion due to degenerative cartilage exclusion criteria: * has systemic bone or cartilage disorders * has significant vascular impairment proximal to implant site * has substantial joint destabilization including extensive osteophyte formation * has substantial surface erosion of the weight-bearing articular cartilage * evidence of infection or fractures in or around the joint * contraindication to bone marrow aspiration * any acute or chronic communicable diseases including hepatitis b, hepatitis c and hiv * any past history of neoplasia and primary hematological disease * renal impairment indicated by serum creatinine greater than 200mm * liver impairment indicated by serum aspartate transaminase and serum alanine transaminase greater than 120 iu * any other co-morbidity which the physician deems as a contraindication to stem cell transplantation and bone marrow biopsy

Keywords: osteoarthritis bone marrow mesenchymal stem cells autologous mild osteoarthritis moderate osteoarthritis
ifr guided coronary artery bypass grafting surgery

Conditions: Ischaemic Heart Disease; Coronary Artery Disease; Coronary Stenosis

Summary: the expected outcome of better and improved patency of bypass grafts and its direct relation to pre-operative ifr measurements of stenosis as compared to direct visual physiology of stenosis in the coronary angiogram. to establish the correlation between the use of intracoronary physiology and improved graft patency at 12 months for patients undergoing cabg surgery. it is a minimum of 28 and a maximum of 100 patients single-centre proof or concept/ observational study/ pilot study.

patients suffering from coronary artery disease undergo coronary artery bypass grafting surgery (cabg) as the standard of care. the selection of which vessels to bypass is usually at the discretion of the surgeon forming an opinion based on the pre-operative angiographic imaging. intra-coronary physiology (ifr measurements) is more accurate to determine the level of damage to the coronary arteries; however, currently it is not used for cabg pre-assessment, but only for percutaneous intervention also known as stenting as it has been shown to improve outcomes. although, the use of intracoronary physiology has not been extensively studied or validated in patients undergoing cabg. patients with multi-vessel coronary artery disease (cad) who are planned for surgical revascularization with coronary artery bypass grafting (cabg), will have ifr measurement taken during invasive coronary angiography as part of standard care, they will undergo cabg and will have echocardiography at 3 months and computed tomography coronary angiography (ctca) at 12 months. early graft failure will be assessed by the presentation of any clinical symptoms, major adverse cardiovascular and cerebrovascular events (macce) and echocardiography at 3 months. the endpoint will be graft patency as assessed by ct coronary angiography at 12 months. anticipated recruitment is 12-24 months. follow-up with echocardiography at 3 months and a ctca at 12 months. quality of life questionnaire will be completed by the patient at 3 and 12 months during the follow-up appointment. patients will continue on optimal medical therapy. clinic visit and quality of life scale questionnaires will be recorded at 3 and 12 months and echocardiography will be assessed at 3 months. graft patency at 12 months will be assessed with a ct coronary angiography.

Eligibility criteria:
inclusion criteria 1. age of 25 to 80 years of age 2. willing to participate and able to understand, read and sign the informed consent form (icf) before standard of care elective cabg surgery 3. undergoing isolated first-time elective cabg surgery 4. available pre-operative angiography data with ifr measurements done during the pre-operative angiography exclusion criteria 1. emergency cabg surgery 2. ejection fraction≤ 40% 3. severe valvular heart disease

Keywords: instantaneous wave-free ratio (ifr) coronary artery bypass grafting (cabg)
assessing and addressing community exposures to environmental contaminants

Conditions: Environmental Exposure

Summary: the purpose of this study is to build on our equitable, eight-year tribal-academic partnership with the ramapough nation of northern nj to advance tradition-centered farming practices and management strategies supporting sustainable food systems to relieve local food insecurity and nutritional deficiency, prevent disease and promote health. furthermore, assessing the extent of environmental contamination, individual toxicant burdens and micronutrient levels and health disorders in ramapough tribal members of both sexes as outlined in the following: * collect in-person/online survey information on demographics, health and food intake, nutrition, food security, and psychosocial stressors, and perform core anthropometric measurements (i.e., height, weight, body mass index, body circumference and blood pressure) at enrollment on tribal members to inform health promotion strategies and community actions. * determine individual-level contaminant burdens and micronutrient concentrations (e.g., iron, calcium, folate, vitamins) in urine and blood from surveyed (sub-aim 1a) ramapough turtle clan volunteers. * test soil, plants and surface water where turtle clan residents live, recreate and attend church in ringwood, nj using a community-based, citizen scientist approach.


Eligibility criteria:
inclusion criteria: * male or female between the age of 18 - 80 years old at the time of enrollment * living on the streets of halifax road, orange turnpike, ramapo ave, 1st-7th streets, mountain avenue and fox hollow road in hillburn, ny; peter's mine road, canon mine road, pipeline road, milligan drive, cable house road and van dunk lane in ringwood, nj; stag hill road, and ramapo brae lane in mahwah, nj * willing and able to provide consent exclusion criteria: * pregnant women and individuals under 18 or over 80 years old * do not live in the identified streets above and/or have lived there for less than 2 years will be excluded from the study

Keywords: ramapough nation metals food nutrition
treating pain to reduce disability among older home health patients

Conditions: Arthritis - Post Surgical; Other Activity-limiting Pain

Summary: the overall goal of this real-world comparative effectiveness research (cer) study is to reduce disability among older home health patients by treating their pain more effectively. to achieve this goal the investigators will conduct a cluster randomized controlled trial of a physical therapist (pt) delivered intervention provided to vnsny home health care patients with activity-limiting pain. the intervention is an evidence-based non-pharmacological program to reduce pain and pain-related disability that utilizes cognitive-behavioral pain self-management (cbpsm) techniques.

this project will compare the effectiveness of usual care provided to older home health patients admitted with activity-limiting pain to usual care plus instruction by pts in cbpsm techniques. the project also will examine differences in the effectiveness of the intervention among different race/ethnicity groups and individuals with different pain types, as well as the fidelity of intervention-group pts to the cbpsm program. the specific aims of this cer study that will include sizeable numbers of hispanics, non-hispanic african americans and non-hispanic white patients ages 55 and older are: (1) to compare the effectiveness of usual care provided to older home health patients admitted with activity-limiting pain to usual care plus instruction by pts in cbpsm techniques; and (2) to examine the heterogeneity of cbpsm treatment effects among patients with different pain conditions and minority group status.

Eligibility criteria:
inclusion criteria: * vnsny patient in the adult home healthcare program * services are being provided in the bronx, brooklyn, manhattan, queens, staten island, nassau or westchester * vnsny plan of care includes physical therapy * age 55 or older * speaks english * has a telephone * activity-limiting pain exclusion criteria: * significant cognitive impairment

Keywords: home care cognitive-behavioral techniques physical therapy pain older adults
ideal study: blinded rct for the impact of ai model for cerebral aneurysms detection on patients' diagnosis and outcomes

Conditions: Intracranial Aneurysm; CT Angiography; Deep Learning; Double Bind Interaction

Summary: this study (iedal study) intends to prospectively enroll more than 6800 patients who will undergo head ct angiography (cta) scanning in the outpatient clinic. it will be carried out in 25 hospitals in more than 10 provinces in china. the patient's head cta images will be randomly assigned to the true-ai and sham-ai group with a ratio of 1:1, and the patients and radiologists are unaware of the allocation. the primary outcomes are sensitivity and specificity of detecting intracranial aneurysms. the secondary outcomes focus on the prognosis and outcomes of the patients.

a multicenter, prospective, double-blind, randomized controlled trial will be conducted (ideal study). patients who are scheduled to undergo cranial ct angiography (cta) scanning will be randomly divided into two groups with a ratio of 1:1, one of the group will be assigned to true-ai aided intracranial aneurysms diagnosis strategy (true-ai group) and the other will be assigned to sham-ai aided intracranial aneurysms diagnosis strategy (sham-ai group, which has a sensitivity close to 0% and a similar specificity to true-ai). the primary outcomes are diagnostic sensitivity and specificity of detecting aneurysms. secondary endpoints include other diagnostic performance indexes for intracranial aneurysms; diagnostic performances for other intracranial lesions for intracranial arterial stenosis, occlusion, and intracranial tumors; detection rates of intracranial lesions according to radiology reports; workload of head cta interpretation; resource use; treatment-related indexes during patient follow-up (e.g. clinical follow-up, hospitalization, rate of patients undergoing dsa); life quality; outcomes of aneurysm-related events; repeat head cta or mra at 12-month follow; cost-effectiveness analysis between intervention and control arm to evaluate the short- and longterm influence of ai system to the routine practice and patients' prognosis and outcomes.

Eligibility criteria:
inclusion criteria: * patients in the outpatient setting who are scheduled to undergo head cta scanning in 25 hospitals in more than 10 provinces in china. exclusion criteria: * age under 18 years. * patients with contraindications to cta. * modified rankin scale (mrs) score \> 3. * refuse to sign informed consent. * participation in other clinical studies of intracranial aneurysms. * patients with failed head cta scanning or incomplete image data, or poor image quality.
spyglass™ discover percutaneous

Conditions: Pancreatic Diseases; Bile Duct Obstruction; Bile Duct Diseases

Summary: to document the clinical utility of percutaneous cholangiopancreatoscopy using a thin, disposable, flexible endoscope for evaluation and treatment of complex pancreaticobiliary disease in a prospective, multi-center case series

this case series aims to illustrate the clinical utility of percutaneous transhepatic cholangiopancreatoscopy using a thin, disposable, flexible endoscope performed by gastroenterological endoscopists and/or interventional radiologists in procedures including but not limited to: * ptcs for tissue diagnosis in cases of surgically or pathologically-altered anatomy, * ptcs for stone removal after surgically or pathologically-altered anatomy, * percutaneous rendezvous to aid ercp after failed endoscopic cannulation, * percutaneous delivery of palliative intraluminal brachytherapy, * intra-procedural percutaneous salvage procedures when an initial route of access fails

Eligibility criteria:
inclusion criteria: 1. scheduled for a percutaneous transhepatic procedure to access the pancreaticobiliary anatomy that will accommodate passage of spyglass™ discover digital catheter per local standard of practice 2. written informed consent from patient or legally authorized representative of the patient exclusion criteria: 1. contraindication for cholangiopancreatoscopy 2. subjects with unresolved adverse event(s) associated with prior percutaneous pancreaticobiliary ductal access 3. \<18 years of age 4. potentially vulnerable subjects, including, but not limited to pregnant women

Keywords: percutaneous transhepatic cholangiopancreatoscopy spyglass discover pancreaticobiliary disease
prevention of cipn using compressive therapy

Conditions: CIPN in Adjuvant Breast Cancer Patients

Summary: chemotherapy-induced peripheral neuropathy (cipn) is a common side effect of treatment with taxanes and platinum-based drugs, significantly impacting the quality of life of oncology patients. symptoms such as reduced sensitivity and pain may persist even after treatment ends. research has shown that compression therapy using gloves and stockings effectively reduces the incidence of cipn, improves patient adherence to treatment, and has no severe side effects. a study at the chemotherapy unit of the comprehensive oncology care clinic, masaryk memorial cancer institute, will investigate the efficacy of this therapy. tight-fitting gloves and compression stockings will be used to limit the flow of cytotoxic agents to peripheral areas. effectiveness will be assessed through quality-of-life questionnaires, hand strength and coordination tests, and laboratory analyses to identify predictive markers of neuropathy. the study aims to enhance cipn prevention and integrate this method into clinical practice.


Eligibility criteria:
inclusion criteria: * age 18-70 years at the time of signing the informed consent (ic). * signed informed consent. * breast cancer stages i-iii * ecog performance status 0-2. * (neo)adjuvant treatment with paclitaxel weekly. exclusion criteria: * metastatic disease. * history of neuropathy/vasculopathy and its pharmacological treatment. * type i or ii diabetes. * stroke within the last 6 months. * prior treatment with taxanes and/or cisplatin derivatives. * peripheral arterial ischemia.

Keywords: cipn breast cancer compressive therapy chemotherapy